OraSure Technologies (OSUR) Aktievy
OraSure Technologies, Inc. tillsammans med sina dotterbolag utvecklar, tillverkar, marknadsför, säljer och distribuerar diagnostiska produkter och utrustning för provtagning i USA, Europa, Afrika och internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 2/6 |
| Framtida tillväxt | 0/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 0/6 |
OSUR Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
OraSure Technologies, Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$3.81 |
| 52 veckors högsta | US$4.58 |
| 52 veckors lägsta | US$2.08 |
| Beta | 1.01 |
| 1 månads förändring | -1.55% |
| 3 månaders förändring | 23.70% |
| 1 års förändring | 36.07% |
| 3 års förändring | -42.27% |
| 5 års förändring | -63.71% |
| Förändring sedan börsintroduktionen | -30.73% |
Senaste nyheter och uppdateringar
Seeking Alpha • Aug 13
OraSure Technologies: Lack Of Near Term Catalysts
Summary OraSure Technologies, Inc. (OSUR) reported a 2Q26 beat on EPS and revenue, with diagnostics and sample management solutions segments flat year-over-year. Gross margin improved to 43.5% driven by internal efficiencies, but non-GAAP operating loss widened to -$14.7 million; GAAP net income was $6.2m due to a non-cash gain. InteliQuick CT/NG FDA submission was withdrawn for revision, delaying launch; Colli-Pee Dx received FDA approval with revenue ramp expected in 2027. OraSure trades at a 2.1x forward P/S, a 42% sector discount, supported by takeover speculation and not strong company fundamentals. I rate the stock as a HOLD. Read the full article on Seeking Alpha
Uppdatering av berättelse • Aug 04
OSUR: At-Home STI Testing And New Diagnostics Will Support Balanced Outlook
OraSure Technologies' analyst price target has been revised from $4.75 to $4.00 as analysts adjust their views on fair value, discount rate, revenue growth assumptions, profit margins, and future price-to-earnings (P/E) expectations. What’s in the News for OraSure Technologies OraSure Technologies received Emergency Use Authorization from the U.S. FDA for its second generation OraQuick Ebola 2.0 Rapid Antigen Test, which is intended for use with whole blood in live patients and cadaveric oral fluid in suspected Ebola cases.Recent updates
Seeking Alpha • Aug 13
OraSure Technologies: Lack Of Near Term Catalysts
Summary OraSure Technologies, Inc. (OSUR) reported a 2Q26 beat on EPS and revenue, with diagnostics and sample management solutions segments flat year-over-year. Gross margin improved to 43.5% driven by internal efficiencies, but non-GAAP operating loss widened to -$14.7 million; GAAP net income was $6.2m due to a non-cash gain. InteliQuick CT/NG FDA submission was withdrawn for revision, delaying launch; Colli-Pee Dx received FDA approval with revenue ramp expected in 2027. OraSure trades at a 2.1x forward P/S, a 42% sector discount, supported by takeover speculation and not strong company fundamentals. I rate the stock as a HOLD. Read the full article on Seeking AlphaUppdatering av berättelse • Aug 04
OSUR: At-Home STI Testing And New Diagnostics Will Support Balanced Outlook
OraSure Technologies' analyst price target has been revised from $4.75 to $4.00 as analysts adjust their views on fair value, discount rate, revenue growth assumptions, profit margins, and future price-to-earnings (P/E) expectations. What’s in the News for OraSure Technologies OraSure Technologies received Emergency Use Authorization from the U.S. FDA for its second generation OraQuick Ebola 2.0 Rapid Antigen Test, which is intended for use with whole blood in live patients and cadaveric oral fluid in suspected Ebola cases.
Uppdatering av berättelse • Jul 20
OSUR: New At-Home STI Testing And Buybacks Will Shape Balanced Outlook
Analysts have raised their price target on OraSure Technologies to $4.00 from $3.50 as they update their models for modestly adjusted revenue growth assumptions, a slightly lower discount rate, and a higher future P/E multiple despite a small trim to projected profit margins. What’s in the News for OraSure Technologies OraSure Technologies received U.S. Food and Drug Administration (FDA) clearance for the Colli-Pee™•Dx Urine Collection Kit from subsidiary DNA Genotek, for use with multiple Roche tests for sexually transmitted infections on cobas® 5800, 6800, and 8800 systems.Uppdatering av berättelse • Jun 28
OSUR: Altai Cooperation Will Likely Fail To Offset Weak Future Returns
Analysts have trimmed their fair value estimate for OraSure Technologies from $4.00 to $3.50, citing updated assumptions regarding the company's discount rate, revenue growth outlook, profit margins, and future P/E multiple. What's in the News OraSure Technologies received U.S. Food and Drug Administration clearance for its Colli-Pee™•Dx Urine Collection Kit from subsidiary DNA Genotek Inc.Uppdatering av berättelse • Jun 14
OSUR: At-Home STI Testing Expansion Will Drive Bullish Long-Term Outlook
OraSure Technologies' analyst price target remains at $4.75. Analysts point to modestly adjusted discount rate, profit margin, and future P/E assumptions as the key valuation tweaks behind the unchanged figure.Uppdatering av berättelse • May 31
OSUR: Altai Agreement And Buybacks Will Shape Balanced Future Outlook
Analysts have trimmed their fair value estimate for OraSure Technologies from $5.00 to $4.75, citing updated assumptions for discount rate, revenue growth, profit margin, and future P/E that collectively point to a slightly more conservative outlook for the stock. What's in the News From January 1, 2026 to March 31, 2026, OraSure repurchased 1,768,017 shares, representing 2.51% of shares, for US$4.99 million, completing a total buyback of 7,050,790 shares, or 9.68%, for US$19.92 million under the program announced on March 24, 2025 (Key Developments).Uppdatering av berättelse • May 02
OSUR: Altai Cooperation And Board Changes Will Support Future Upside
Analysts have nudged their price target on OraSure Technologies slightly higher to $4.00, reflecting updated assumptions around the discount rate, modest revenue growth expectations, profit margin adjustments, and a revised future P/E multiple. What's in the News On April 17, 2026, OraSure Technologies entered into a Cooperation Agreement with Altai Capital Management that includes appointing John D.Uppdatering av berättelse • Apr 18
OSUR: Altai Cooperation Agreement Will Drive Future Upside Potential
Analysts have adjusted their price target on OraSure Technologies to reflect a fair value of $5.00, citing updated assumptions for the discount rate, profit margin, and future P/E ratio as the key drivers of this change. What's in the News On April 17, 2026, OraSure Technologies entered into a Cooperation Agreement with Altai Capital Management, adding John D.Uppdatering av berättelse • Apr 01
OSUR: Activist Campaign And Governance Changes Will Support Future Upside
Analysts have made a modest adjustment to their price target for OraSure Technologies to $4.00, reflecting updated assumptions for the discount rate, revenue growth, profit margin, and future P/E multiple. What's in the News Altai Capital Management has escalated its campaign, calling for a broad review of options including a potential sale of OraSure Technologies, criticizing executive pay and board oversight, and urging shareholders to support its director nominees Rishi Bajaj and John Bertrand at the 2026 annual meeting (Investor Activism, March 18, 2026).Uppdatering av berättelse • Mar 18
OSUR: Activist Board Push And Buybacks Will Support Future Upside
Analysts have lifted their price target on OraSure Technologies to $4.00 from $3.00, citing updated expectations regarding revenue growth, profit margins, and a modestly higher future P/E multiple. What's in the News Altai Capital Management sent a letter to OraSure's board on March 17, 2026, outlining a five-pillar case for change, citing share price underperformance, board ownership levels, CEO pay structure, a call for a strategic review, and support for its nominees, Rishi Bajaj and John Bertrand, to join the board (Investor Activism) Altai Capital formally nominated Bajaj and Bertrand for election to the board at the 2026 Annual Meeting and submitted a proposal to declassify the board so all directors stand for annual elections (Investor Activism) OraSure issued first quarter 2026 guidance, projecting total revenues of US$26 million to US$29 million, with only a negligible contribution from COVID 19 testing (Corporate Guidance) The company reported completing a share repurchase of 5,245,180 shares, or 7.12% of its stock, for US$14.89 million under a buyback program announced on March 24, 2025, including 1,900,000 shares bought for US$5 million between October 1 and December 31, 2025 (Buyback Tranche Update) OraQuick HIV Self Test received a Health Canada license as the first oral HIV self test in Canada, offering 20 minute results from an oral swab and distribution through St. Michael's Hospital to support access across healthcare and community settings (Product Related Announcement) Valuation Changes Fair Value: The analyst fair value estimate has risen from $3.00 to $4.00 per share, which represents a material upward revision to the target level.Uppdatering av berättelse • Mar 04
OSUR: New STI Self Testing Submissions Will Drive Future Upside
Analysts have raised their price target on OraSure Technologies from $4.50 to $5.00, citing updated assumptions around revenue growth, profit margin and future P/E that they state better reflect the company’s current outlook. What's in the News OraSure completed a share repurchase tranche between October 1, 2025 and December 31, 2025, buying 1,900,000 shares, or 2.63% of shares, for US$5 million.Uppdatering av berättelse • Feb 18
OSUR: New STI Self Testing Submissions Will Support Future Shareholder Upside
Narrative Update on OraSure Technologies Analysts have kept their OraSure Technologies fair value estimate steady at $4.50, with only marginal tweaks to inputs like the discount rate, long term revenue growth, profit margin, and future P/E assumptions driving this maintained price target. What's in the News OraQuick HIV Self-Test received a Health Canada license, becoming Canada's first oral HIV self test and offering results in about 20 minutes from an oral swab for HIV 1 and HIV 2 antibodies.Uppdatering av berättelse • Feb 04
OSUR: New STI Testing Submissions Will Drive Future Shareholder Value
Analysts have modestly revised their price target for OraSure Technologies to US$4.50, reflecting slightly adjusted assumptions on discount rate, revenue growth, profit margin, and future P/E. These changes leave their overall view of the company’s fair value essentially unchanged.Uppdatering av berättelse • Jan 21
OSUR: At-Home STI Testing Pipeline Will Drive Future Upside
Analysts have maintained their price target on OraSure Technologies at US$3.00. This reflects updated views on factors such as discount rate, revenue growth assumptions, profit margins, and future P/E expectations, while keeping the headline valuation level unchanged.Uppdatering av berättelse • Jan 07
OSUR: At-Home STI Testing And Activist Push Will Drive Future Upside
Analysts have kept their fair value estimate for OraSure Technologies steady at US$3.00 per share, citing largely unchanged assumptions around the company’s discount rate, revenue growth outlook, profit margin profile, and future P/E multiple. What's in the News OraSure submitted two applications to the U.S. FDA at the end of 2025 for clearance of a rapid molecular self-test for Chlamydia trachomatis and Neisseria gonorrhoeae and for its Colli-Pee at-home urine collection device for sexually transmitted infections, both aimed at over-the-counter and at-home use (Key Developments).Uppdatering av berättelse • Dec 23
OSUR: Activist Board Challenge Will Drive Future Shareholder Value Upside
Analysts have reduced their price target on OraSure Technologies from 5.00 dollars to 3.00 dollars per share, citing a higher required return on equity and lower expected future valuation multiples, despite improving revenue growth assumptions and largely stable profit margins. What's in the News Altai Capital Management notified OraSure Technologies Board on December 17, 2025 of its intention to nominate two directors at the 2026 annual meeting, citing share price underperformance and capital allocation concerns (Key Developments).Uppdatering av berättelse • Dec 09
OSUR: Ongoing Share Repurchases Will Drive Future Shareholder Value
Analysts have raised their price target on OraSure Technologies from 4.50 dollars to 4.75 dollars, citing slightly lower discount rate assumptions and a modestly higher long term valuation multiple, despite a small reduction in projected profit margins. What's in the News Completed a share repurchase of 3,345,180 shares, representing 4.49% of outstanding shares, for a total of $9.89 million under the buyback program announced on March 24, 2025 (Key Developments) From July 1, 2025 to September 30, 2025, repurchased 1,524,424 shares, or 2.07% of outstanding shares, for $4.9 million as the latest tranche of the ongoing buyback (Key Developments) Issued fourth quarter 2025 earnings guidance, projecting total revenues of $25 million to $28 million (Key Developments) Q4 2025 outlook includes less than $100,000 in COVID-19 testing revenue, underscoring the company’s pivot away from pandemic-driven sales (Key Developments) Valuation Changes Fair Value Estimate remains unchanged at 4.50 dollars per share, indicating no revision to the intrinsic value assessment.Uppdatering av berättelse • Nov 25
OSUR: Share Buybacks And Board Actions Will Drive Shareholder Value
Narrative Update: Analyst Price Target Adjustment for OraSure Technologies Analysts have reduced OraSure Technologies’ price target from $4.75 to $4.50, citing updated assumptions in growth and profitability metrics. What's in the News OraSure Technologies repurchased 1,524,424 shares for $4.9 million during Q3 2025, completing a total buyback of 3,345,180 shares under the repurchase plan announced in March 2025 (Key Developments).Analysartikel • Nov 14
Revenues Working Against OraSure Technologies, Inc.'s (NASDAQ:OSUR) Share Price Following 25% Dive
OraSure Technologies, Inc. ( NASDAQ:OSUR ) shares have had a horrible month, losing 25% after a relatively good period...Uppdatering av berättelse • Nov 06
OSUR: Activist Pressure Will Drive Shareholder Value Amid Board Challenge
Analysts have revised their price target for OraSure Technologies from $6.00 to $4.75, citing updated projections for revenue growth and broader shifts in valuation estimates. What's in the News Healthcare entrepreneur Ron Zwanziger warned OraSure that he may pursue an adversarial strategy if the company continues to resist his acquisition bid, following OraSure's rejection of his all-cash offer earlier this summer (Reuters).Analysartikel • Aug 08
OraSure Technologies, Inc. (NASDAQ:OSUR) Analysts Are Pretty Bullish On The Stock After Recent Results
There's been a notable change in appetite for OraSure Technologies, Inc. ( NASDAQ:OSUR ) shares in the week since its...Analysartikel • May 08
Shareholders Will Probably Hold Off On Increasing OraSure Technologies, Inc.'s (NASDAQ:OSUR) CEO Compensation For The Time Being
Key Insights OraSure Technologies will host its Annual General Meeting on 14th of May Total pay for CEO Carrie Eglinton...Analysartikel • Feb 27
Investors Don't See Light At End Of OraSure Technologies, Inc.'s (NASDAQ:OSUR) Tunnel And Push Stock Down 26%
OraSure Technologies, Inc. ( NASDAQ:OSUR ) shareholders won't be pleased to see that the share price has had a very...
Ny berättelse • Feb 09
Launch Of OraQuick HCV Self-Test And Genomics Ventures Will Open Markets Amid Profitability Pressures
The international launch of the OraQuick HCV Self-test and upcoming blood proteomics launch offer significant revenue and growth opportunities.Seeking Alpha • Dec 11
OraSure Technologies: Discounted Assets With An Attractive Free Call Option
Summary OraSure Technologies is undervalued, trading below its net current asset value, offering a compelling risk-reward scenario with limited downside risk. The company has a robust balance sheet with no long-term debt and $280 million in cash, mitigating downside risks. Post-COVID margins are expected to improve, driving positive cash flow and substantial upside potential, with a projected 70%+ appreciation. Management is competent and aligned with shareholders, enhancing confidence in the company’s ability to capitalize on its undervaluation. Read the full article on Seeking AlphaAnalysartikel • Nov 14
Some May Be Optimistic About OraSure Technologies' (NASDAQ:OSUR) Earnings
Shareholders appeared unconcerned with OraSure Technologies, Inc.'s ( NASDAQ:OSUR ) lackluster earnings report last...Analysartikel • Nov 08
Here's What Analysts Are Forecasting For OraSure Technologies, Inc. (NASDAQ:OSUR) After Its Third-Quarter Results
OraSure Technologies, Inc. ( NASDAQ:OSUR ) just released its third-quarter report and things are looking bullish...Seeking Alpha • Nov 04
OraSure: An NCAV Diamond In The COVID Rough
Summary OraSure Technologies Inc. is a health and wellness company specializing in "easy to use" diagnostic and specimen collection products. OraSure has a strong balance sheet and is trading below its net current asset value. At the same time, OraSure has a stable operational history with consistent normalized cash flow margins. OraSure has the potential to return to its (much higher) historical NCAV multiples, particularly when considering the new management teams' focus on operational efficiency through cost control. Read the full article on Seeking AlphaSeeking Alpha • Sep 10
OraSure Technologies: Nursing A COVID-19 Hangover
Summary Today, we revisit OraSure Technologies, Inc., a diagnostic firm that, like many in the industry, is going through a post-COVID hangover. The good news for the company is it is sitting on a huge cash balance and management is doing a good job of reducing operating expenses. An updated analysis around OraSure Technologies follows in the paragraphs below. Read the full article on Seeking AlphaAnalysartikel • May 11
OraSure Technologies, Inc. (NASDAQ:OSUR) Just Reported Earnings, And Analysts Cut Their Target Price
It's been a sad week for OraSure Technologies, Inc. ( NASDAQ:OSUR ), who've watched their investment drop 11% to...Analysartikel • Apr 17
Lacklustre Performance Is Driving OraSure Technologies, Inc.'s (NASDAQ:OSUR) Low P/S
With a price-to-sales (or "P/S") ratio of 1x OraSure Technologies, Inc. ( NASDAQ:OSUR ) may be sending very bullish...Aktieägarnas avkastning
| OSUR | US Medical Equipment | US Marknad | |
|---|---|---|---|
| 7D | -4.8% | 2.7% | 0.6% |
| 1Y | 36.1% | -11.6% | 20.1% |
Avkastning vs industri: OSUR översteg US Medical Equipment branschen som gav -11.6 % under det senaste året.
Avkastning vs Marknaden: OSUR översteg US marknaden som gav 20.1 % under det senaste året.
Prisvolatilitet
| OSUR volatility | |
|---|---|
| OSUR Average Weekly Movement | 7.5% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stabil aktiekurs: OSUR har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: OSUR s veckovolatilitet ( 7% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1987 | 500 | Carrie Eglinton Manner | www.orasure.com |
OraSure Technologies, Inc. tillsammans med sina dotterbolag utvecklar, tillverkar, marknadsför, säljer och distribuerar diagnostiska produkter och utrustning för provtagning i USA, Europa, Afrika och internationellt. Företaget erbjuder OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test (international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, SickleSCAN test och OraSure oral fluid collection device för HIV-1 antikroppar; Intercept drogtestsystem; immunoassaytester och reagenser; och Q.E.D. salivalkoholtest. Företaget tillhandahåller också genomiska produkter under varumärkena Oragene och ORAcollect för insamling av genetiskt material från mänsklig saliv, Colli-Pee insamlingsanordningar för volymetrisk insamling av urinprover och HEMAcollect proteinblodinsamlingsanordning.
OraSure Technologies, Inc. Sammanfattning av grunderna
| OSUR grundläggande statistik | |
|---|---|
| Börsvärde | US$264.84m |
| Vinst(TTM) | -US$49.13m |
| Intäkter(TTM) | US$112.41m |
2.3x
P/S-förhållande-5.3x
P/E-förhållandeÄr OSUR övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| OSUR resultaträkning (TTM) | |
|---|---|
| Intäkter | US$112.41m |
| Kostnad för intäkter | US$64.49m |
| Bruttovinst | US$47.93m |
| Övriga kostnader | US$97.05m |
| Intäkter | -US$49.13m |
Senast redovisade vinst
Jun 30, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -0.71 |
| Bruttomarginal | 42.63% |
| Nettovinstmarginal | -43.70% |
| Skuld/egenkapitalförhållande | 0% |
Hur har OSUR utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/08/17 00:01 |
| Aktiekurs vid dagens slut | 2026/08/17 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
OraSure Technologies, Inc. bevakas av 15 analytiker. 1 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Charley Jones | Barrington Research Associates, Inc. |
| Karen Koski | BTIG |
| Mark Massaro | Canaccord Genuity |